Pulmatrix (NSDQ:PULM) said today that the first patient was treated in a first-in-human study of Pulmazole – an inhaled formulation of the anti-fungal drug, itraconazole.
The Lexington, Mass.-based company is evaluating its iSperse formulation of the drug as a treatment for asthma patients who have developed allergic bronchopulmonary aspergillosis.
Get the full story at our sister site, Drug Delivery Business News.
The post Pulmatrix doses first patient in Ph1 Pulmazole trial appeared first on MassDevice.